Informist, Tuesday, Aug. 5, 2025

--Alembic Pharma Apr-Jun consol net profit INR 1.54 bln

--Analysts saw Alembic Pharma Apr-Jun consol net profit INR 1.63 bln

--Alembic Pharma Apr-Jun consol PAT INR 1.54 bln vs INR 1.35 bln year ago

--Alembic Pharma Apr-Jun consol revenue INR 17.1 bln vs INR 15.6 bln yr ago

By Rizwan Ali

MUMBAI- Alembic Pharmaceuticals Ltd. missed the Street's estimates for both revenue and the net profit for the June quarter. The company reported a net profit of INR 1.54 billion for the June quarter, lower than the estimate of INR 1.63 billion. The net profit rose 14.6% from INR 1.35 billion in a year-ago quarter.

Alembic Pharma reported revenue from operations of INR 17.1 billion for the June quarter, up 9.5% from INR 15.6 billion in the year-ago quarter. The top line missed analysts' estimate of INR 17.25 billion.

The company's total expense during the quarter came in at INR 15.27 billion, up 8.5% from INR 14.07 billion in the year-ago quarter. Other expenses of the company rose 8.7% to 5.99 billion, from INR 5.51 billion a year ago. Finance cost jumped 78% to INR 235 million from INR 131 million on year.

The pharmaceutical company reported earnings before interest, taxes, depreciation, and amortisation of INR 2.88 billion in the reporting quarter, up nearly 21% on year from INR 2.39 billion. The EBITDA margin of the company expanded 170 basis points on year to 17%.

Losses in inventories, finished goods, stock in trade and work in progress rose to INR 1.33 billion in Apr-Jun from INR 1.07 billion in the year-ago quarter. The cost of materials consumed increased 6.2% on year to INR 4.31 billion, and purchase of stock in trade rose 14.3% to INR 1.09 billion. Employee benefit expenses increased to INR 4.23 billion, up 11.3% on year.

Revenue from the domestic branded business grew to INR 5.99 billion during the quarter, up 5% from INR 5.72 billion in year-ago quarter. Revenue from its US generics business was INR 5.23 billion, up 13% from INR 4.61 billion a year ago. The revenue growth in this segment was driven by the ramp up of key product launches and market share gains in select therapies. Revenue from the generics segment, excluding the US, also jumped 21% on year to INR 3.28 billion.

The company's active pharmaceutical ingredients sales rose 1% on year to INR 2.61 billion during the quarter. The segment was hit by price erosion, which was partially offset by volume growth. Its animal health business clocked a revenue of INR 1.14 billion during the quarter, up 16.8% from INR 976 million in a year-ago quarter.

Shares of the company briefly rose over 2% to a high of INR 997 after reporting its June quarter earnings. However, at 1438 IST, the stock was back at earlier levels, trading 2% lower at INR 948.35 on National Stock Exchange. End

IST, or Indian Standard Time, is five-and-a-half hours ahead of GMT

Edited by Akul Nishant Akhoury

For users of real-time market data terminals, Informist news is available exclusively on the NSE Cogencis WorkStation.

Cogencis news is now Informist news. This follows the acquisition of Cogencis Information Services Ltd by NSE Data & Analytics Ltd, a 100% subsidiary of the National Stock Exchange of India Ltd. As a part of the transaction, the news department of Cogencis has been sold to Informist Media Pvt Ltd.

Informist Media Tel +91 (22) 6985-4000

Send comments to feedback@informistmedia.com

© Informist Media Pvt. Ltd. 2025. All rights reserved.